Soft Mist Inhalers Market Research Report Information By Product Type (Disposable and Reusable), By Age Group (Adult and Pediatric), By Application (Asthma and COPD), By Distribution Channel (Hospital pharmacies, Retail pharmacies and Online pharmacies), By End-use (Hospitals and clinics, Homecare settings and Other end users) and By Region (North America, Europe, Asia-Pacific and Rest Of The World) –Market Forecast Till 2032

Global Soft Mist Inhalers Market Overview

Soft Mist Inhalers Market Size was valued at USD 2.6 Billion in 2023. The Soft Mist Inhalers market industry is projected to grow from USD 2.8 Billion in 2024 to USD 4.5 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.00% during the forecast period (2024 - 2032). 

The increasing frequency of respiratory illnesses requiring inhalation therapy among patients is one of the key market drivers driving the expansion of the marketplace.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Soft Mist Inhalers Market Trends

• 
  

  Increasing prevalence of  respiratory diseases is driving the market growth

  
  

Market CAGR for Soft Mist Inhalers is being driven by the increasing prevalence of respiratory diseases. Treatment for chronic lung diseases requires medical treatment using respiratory inhalers. Among the equipment used to deliver medication straight to the airways are nebulizers, dry powder inhalers, soft mist inhalers and metered-dose inhalers (MDIs). Furthermore, the fact that the prevalence of respiratory disorders, especially those affecting the pulmonary system, including asthma and COPD, has increased in direct proportion to the growth in the world population. 

Thus, it is becoming more and more important to have contemporary drug delivery methods that provide novel therapy options for a range of illnesses. This is predicted to cause the soft mist inhaler market to expand dramatically globally in the next years. Drug distribution with inhalers is a common medical practice. The need for gentle mist inhalers is obviously growing as new technology proliferates. This is partly because of their natural convenience and capacity to transport drugs to the exact site in the body where they function. This could result in a notable increase in the global soft mist inhaler market in the next years.

The growing incidence of chronic respiratory diseases, including asthma and COPD, along with the need for more effective inhalation delivery methods, is predicted to drive a fast growth in the global soft mist inhaler (Respimat, SMI) market in the following years. Growing demand for economically cost solutions and growing awareness of its advantages are expected to drive the SMI technology sector. 

Another factor predicted to boost market expansion is the launch of state-of-the-art and creative SMI products that provide patients with more comfort and convenience. For instance, by 2022, 11.7 million Americans, or 4.6% of the US population, will have chronic bronchitis, emphysema, or chronic obstructive lung disease. Top it all, in 2021, the Centers for Disease Control and Prevention (CDC) projects that 8.0% of people will have asthma. Thus, result in driving the Soft Mist Inhalers market revenue.

Soft Mist Inhalers Market Segment Insights

Soft Mist Inhalers Product Type Insights

The Soft Mist Inhalers Market segmentation, based on Product Type, includes Disposable and Reusable. The reusable category controlled the market in 2023. Patients may pick the pharmaceutical formulations they want and change doses as needed using reusable SMIs. Both therapeutic compliance and pleasure may rise with this personalization.

Soft Mist Inhalers Age Group Insights

The Soft Mist Inhalers Market segmentation, based on Age Group, includes Adult and Pediatric. The adult category peaked in 2023. Adult respiratory disorders may be more prevalent among smokers, people who work in hazardous conditions, or those who lead alternative lifestyles. Considering the above-described circumstances, the rising incidence of respiratory disorders in adults has led to an increased need for pharmaceutical inhalers, particularly light mist inhalers.

Soft Mist Inhalers Application Insights

The Soft Mist Inhalers Market segmentation, based on Application, includes Asthma and COPD. The market leader in 2023 was expected to be asthma. Metered dose and gentle mist inhalers are growing in popularity at the same time as major pharmaceutical firms are spending more money on research and development of improved asthma inhalers.

Soft Mist Inhalers Distribution Channel Insights

The Soft Mist Inhalers Market segmentation, based on Distribution Channel, includes Hospital pharmacies, Retail pharmacies and Online pharmacies. Hospital pharmacies dominated the market in 2023. As they treat acute respiratory illnesses, including asthma and COPD flare-ups, hospital pharmacies are essential. Usually provided by hospital pharmacists, soft mist inhalers make it easier to promptly give various bronchodilators and associated drugs.

Soft Mist Inhalers End-use Insights

The Soft Mist Inhalers Market segmentation, based on End-use, includes Hospitals and clinics, Homecare settings and Other end users. The hospitals and clinics category was the revenue-rich category by 2023. As soft mist inhalers are routinely given to patients with respiratory illnesses in both settings to guarantee uniformity of treatment, hospitals and clinics are the main end consumers of them.

Figure 1: Soft Mist Inhalers Market, by End-use, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Soft Mist Inhalers Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Soft Mist Inhalers market area will dominate this market. Improved inhalation treatment is becoming more and more necessary as respiratory disorders, including asthma and chronic obstructive lung disease, become more common.

Further, the major countries studied in the market report are Brazil, South Korea, China, Japan, India, Australia, Germany, France, the UK, Italy, Spain, Canada and the US.

Figure 2: Soft Mist Inhalers Market Share By Region 2023 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Soft Mist Inhalers market has the second-largest portion of the market. This is because chronic obstructive pulmonary disease (COPD) and asthma are becoming more and more common respiratory disorders. Further, the German Soft Mist Inhalers market had the biggest market share and the UK Soft Mist Inhalers market was the European market with the quickest rate of growth.

The Asia-Pacific Soft Mist Inhalers Market is expected to expand between 2024 and 2032 at the quickest CAGR. Since more individuals are aware of their ability to treat respiratory disorders, SMI devices are in greater demand. Moreover, China’s Soft Mist Inhalers market had the biggest market share and the Indian Soft Mist Inhalers market was the Asia-Pacific region's fastest-growing market.

Soft Mist Inhalers Key Market Players & Competitive Insights

Leading market players are introducing a lot of funds on research and development to increase the variety of products they offer, thereby stimulating the market for soft mist inhalers. Furthermore, industry participants are undertaking a variety of strategic initiatives in an effort to expand their global footprint, with important market developments encompassing increased investment, contracting, M&A transactions, product launches and collaborations with other businesses. To expand and persist in a market that is becoming more competitive and dynamic, the Soft Mist Inhalers industry must offer products at reasonable prices.

One of the principal business strategies employed by manufacturers to reduce operational expenses is local production in the global Soft Mist Inhalers industry to help customers and expand the market segment. In recent years, the Soft Mist Inhalers industry has contributed significantly to how medicine has advanced. Major players in the Soft Mist Inhalers market, including Recipharm, Boehringer, Ingelheim am Rhein, Germany, Merxin Ltd, DSB Medical Co., Ltd., Resyca BV, Aero Pump GmbH and Ursatec GmbH and others are undertaking research and development endeavors with the aim of increasing market demand.

Recipharm AB is a pharmaceutical contract development and manufacturing company with headquarters in Spain, Portugal, Israel, and the United States, among the top five globally. Further locations for industrial activities include Portugal, Spain, the UK, France, Germany, Italy and Spain. Across its more than thirty sites, the Swedish company employs around 9,000 people. 

One of the many services our company provides pharmaceutical firms worldwide is the wide selection of available dosage forms. Recipharm completed their initial public offering (IPO) on the Stockholm Stock Exchange in April of 2014. Recipharm was acquired by the private equity company EQT for $2.1 billion in February 2021. Thomas Eldered will remain on the board of Recipharm when Mark Funk takes over as CEO in March 2021.

Inhaler device platforms, both custom and generic, are developed and marketed by Merxin Ltd. Products we sell include no heat, no PG vape devices, capsule dry powder inhalers, multidose dry powder inhalers, soft mist inhalers and equipment made expressly to deliver cannabis to the lungs and nasal passages. To create final dosage forms meant for patient and consumer distribution, clients interface the medication formulation with Merxin Ltd. device platforms. Merxin will have advanced the area of soft mist inhalers significantly by 2023. These devices provide a more sensible option for those with asthma, bronchitis and chronic obstructive pulmonary disease (COPD).

Key Companies in the Soft Mist Inhalers market include

• Recipharm


• Boehringer, Ingelheim am Rhein, Germany


• Merxin Ltd


• DSB Medical Co., Ltd.


• Resyca BV


• Aero Pump GmbH


• Ursatec GmbH

Soft Mist Inhalers Industry Developments

March 2024: Boehringer-Ingelheim will limit eligible inhaler product out-of-pocket costs to USD 35 per month starting in March 2024. With this program, individuals with uninsured or underfunded insurance have more affordably priced alternatives for necessary inhaler supplies, which lowers their costs.

March 2023: Recipharm and Stevanato Group formed a strategic alliance with the intention of improving soft mist inhalers used in the biopharmaceutical and pharmaceutical industry.

Soft Mist Inhalers Market Segmentation

Soft Mist Inhalers Product Type Outlook

• Disposable


• Reusable

Soft Mist Inhalers Age Group Outlook

• Adult


• Pediatric

Soft Mist Inhalers Application Outlook

• Asthma


• COPD

Soft Mist Inhalers Distribution Channel Outlook

• Hospital pharmacies


• Retail pharmacies


• Online pharmacies

Soft Mist Inhalers End-use Outlook

• Hospitals and clinics


• Homecare settings,


• Other end users

Soft Mist Inhalers Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America